Stock Ratings / Health Care / INNV / insiders

USPH (70) OMDA (53) PNTG (64) TDOC (55) ⌘ Pro Terminal →

InnovAge Holding Corp. (INNV) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$9.19 -0.54% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.16

InnovAge Holding Corp. (INNV) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $1.25B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INNV Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INNV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, InnovAge Holding Corp. (NASDAQ: INNV) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $9.19 (-0.54% 1D, market cap $1.25B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, INNV ranks #244 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INNV compare to USPH and OMDA in the Health Care sector?

▼

Within the Health Care sector (Medical/Nursing Services), INNV carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 18.0%, and ROIC of -10.2%. By comparison, USPH (U.S. Physical Therapy Inc.) holds a B- grade (70/100 RQD, P/E 32.6x, ROIC 11.5%, cap $1.28B) and OMDA (Omada Health Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -15.7%, cap $1.15B). Among the 5-stock peer group, USPH leads on earnings multiple (32.6x) while USPH leads on capital efficiency (11.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INNV?

▼

Per INNV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001834376), InnovAge Holding Corp. generated $853.7M in revenue (+11.8% YoY), -$30.3M in net income, and $26.6M in free cash flow against $527.5M in total assets and $56.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.16 (-0.29%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 3.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INNV)Realized 20D OHLCV Swing Band: ±7%

Deterministic 5-Pillar Attribution (52/100 Composite)

🔍 WHY INNV SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (25% of score)

FRED Regime × Technicals: 60% of 52W Range • RSI-14 at 45.9 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 3.1% FCF Margin ($26.6M FCF) & 18% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution7/20 pts (-13 pt drag)

Disciplined Float (+0.16% YoY Shares) & executive Form 4 sales trim 13 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$9.02+1.4% Next Q

Q2 (-2Q)

Grade D$9.15-0.3% Next Q

Q3 (-1Q)

Grade D$9.12+0.8% Next Q

Current

Grade D+$9.19-1.1% Hist 90D α

Trajectory: D (44) → D+ (52)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a INNV Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While INNV currently carries a cautious 52/100 (D+) rating due to Insider Conviction & Share Dilution (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.77) and Max Pain ($9.65) forces dealer call-delta covering toward $13.27.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INNV• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INNV Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 52%NO 48%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

INNV Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (INNV)

No recent open-market Form 4 cluster sales or emergency dumps flagged on INNV. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INNV)

✓Walkthrough of INNV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INNV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +12.48%🛡️ HOLDING TREND SUPPORT

2026-11-03O $9.24H $9.24L $9.19C $9.19VOL 593.1K

RES: $11.78SUP: $8.86SMA50: $9.77SMA200: $9.10

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INNV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INNV Butterfly Map → + Track INNV →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +11.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INNV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INNV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INNV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INNV)

Health Care Rank #244 of 1016 ⚔️ USPH vs INNV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INNV vs. USPH, OMDA, PNTG, TDOC)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, InnovAge Holding Corp. (INNV) ranks #244 by composite RQD confidence (52/100, grade D+) and #327 by equity capitalization ($1.25B). Within this direct 5-issuer industry benchmark cohort, USPH leads on earnings valuation at 32.6x trailing P/E, while USPH leads on capital efficiency and profitability with 11.5% ROIC and 19.2% gross margin. USPH currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with INNV at 52/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INNV ACTIVE InnovAge Holding Corp.	D+	52/100	—	18.0%	-10.2%	-0.54%	$1.25B	Benchmark Subject
USPH U.S. Physical Therapy Inc.	B-	70/100	32.6x	19.2%	11.5%	-0.85%	$1.28B	/usph-vs-innv →
OMDA Omada Health Inc.	D+	53/100	—	65.7%	-15.7%	-4.68%	$1.15B	/omda-vs-innv →
PNTG The Pennant Group Inc.	C	64/100	50.2x	—	11.0%	-1.93%	$1.46B	/pntg-vs-innv →
TDOC Teladoc Health Inc.	D+	55/100	—	—	-17.0%	-2.52%	$1.55B	/tdoc-vs-innv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001834376

In its most recent audited fiscal period (FY2025, filed 2025-06-30), InnovAge Holding Corp. (INNV) reported GAAP revenue of $853.7M (+11.8% vs. FY2024 revenue of $763.9M , and +24.1% cumulative change since FY2023) , GAAP net income of -$30.3M, operating cash flow of $32.9M, and free cash flow of $26.6M (+159.4% YoY). On the balance sheet, INNV closed FY2025 with $527.5M in total assets against $56.0M in total debt (Altman Z-Score: 4.47, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$853.7M	-$30.3M	$32.9M	$26.6M	$527.5M	$56.0M
FY2024 (FY)	2024-06-30	$763.9M	-$21.3M	-$36.9M	-$44.8M	$524.8M	$59.8M
FY2023 (FY)	2023-06-30	$688.1M	-$40.7M	$20.2M	$20.2M	—	—

3. INNV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INNV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does INNV compare to USPH and OMDA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for INNV?

Where is INNV trading relative to its 50-day, 200-day, and 52-week technical levels?

INNV last traded at $9.19 (-0.54% on volume of 593,067 shares), positioning the stock -5.94% below its 50-day simple moving average ($9.77) and +0.99% above its 200-day simple moving average ($9.10). Across its 52-week range of $3.93 to $12.64, INNV sits at the 60.4% percentile with a 14-day RSI of 45.9 (NEUTRAL RANGE) and an implied next-earnings move of ±7.0% ($8.55 to $9.83).

INNV Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are INNV insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies INNV leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: INNV RQD Cockpit INNV 12M Forecast INNV Earnings & Move INNV Dividends & DRIP INNV Insiders & 13F INNV Whale Options INNV Profit Sankey INNV News & Why

Sector Peer Dials

Compare →

USPH B-

U.S. Physical Therapy Inc.

The Pennant Group Inc.

GeneDx Holdings Corp. (Class A)

47 /100

INNV Core Snapshot

Market Cap $1.25B

Trailing / Fwd P/E — / —

Gross Profit Margin 18.0%

Return on Capital (ROIC) -10.2%

Free Cash Flow Yield 2.11%

12M Base Price Target $8.94

FREE TRADER TOOLS

Own INNV Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With INNV → 🏆 Trade INNV in $100K Prop Arena →

INNV Wire

Why It Moved →

Direct Company Event Yahoo Finance • 17h ago

Earnings To Watch: InnovAge Holding Corp (INNV) Q1 2027 -- GF Value Sees 20% Downside

Direct Company Event GuruFocus • 20h ago

InnovAge (INNV) Chief Legal Officer Nicole Damato Sells 3,402 Sh

Direct Company Event MarketBeat • 23h ago

InnovAge Holding Corp. (NASDAQ:INNV) Stock Short Interest Declines 57.0%

Direct Company Event Quiver Quantitative • 1d ago

InnovAge Holding Corp. ($INNV) CEO 2026 Pay Revealed

Direct Company Event MarketBeat • 1d ago

Insider Selling: InnovAge (NASDAQ:INNV) Insider Sells 3,402 Shares of Stock

ROARABLE RATING BRIEF • RQD 52/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

INNV — InnovAge Holding Corp.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:29:59Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, INNV scores 52 out of 100 with a letter grade of D+, labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine at 12/20 (ROIC of -10.2%; FCF yield of 2.11%), Whale 13F Flow at 8/20 (institutional accumulation and options positioning), Insider Conviction at 7/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 13/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 12/20 (Altman Z 4.47; Piotroski F 6/9; Debt/Equity 0.22). Taken together, the lowest-scoring pillars are the ones most tied to shareholder return on capital and to insider and institutional conviction. For a prospective investor, the upside case rests on the balance sheet, which the rating treats as relatively sound, and on a 52-week range of $3.93 to $12.64 against a current price of $9.24, which shows the stock has already moved substantially in both directions. The valuation tradeoff is that the rating's weakest inputs are negative ROIC and thin cash-flow yield, meaning the market price is not currently supported by a demonstrated return on invested capital. Insider and whale signals are the other side of this tradeoff: they point to limited conviction rather than an active accumulation thesis. These are educational observations drawn from the rating components, not personalized advice.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$853.7M	$-29.8M	$-30.3M	N/A	$26.6M	$83.2M	$56.0M
FY 2024	$763.9M	$-23.2M	$-21.3M	N/A	$-44.8M	$46.1M	$59.8M
FY 2023	$688.1M	$-49.4M	$-40.7M	N/A	$20.2M	N/A	N/A

Per the SEC financials, revenue rose from $688.1M (FY 2023) to $853.7M (FY 2025), while operating and net income remained negative in each reported period. Per the market data, gross margin is 18%, operating margin is -3.5%, and net margin is -3.6%, with ROIC at -10.2%. Per the RQD rating, the Altman Z-Score is 4.47 and the Piotroski F-Score is 6/9. The balance sheet shows Debt/Equity of 0.22, with FY 2025 cash of $83.2M against debt of $56.0M.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the catalysts are largely insider-transaction and market-commentary items. A Yahoo Finance report titled "Earnings To Watch: InnovAge Holding Corp (INNV) Q1 2027 -- GF Value Sees 20% Downside" flags a valuation downside view. A GuruFocus item reports that the Chief Legal Officer, Nicole Damato, sold 3,402 shares. A MarketBeat item reports that short interest declined 57.0%. A Quiver Quantitative item covers the CEO's 2026 pay. A MarketBeat item reports insider Carson Anderson and Stow Welsh sold 1,500,000 shares. Each item is flagged YELLOW. Per the Butterfly Supply-Chain Graph, there are no proprietary signals and no butterfly links.

Open Questions

What are the reported EPS and forward earnings figures, given that EPS is N/A across all reported periods and P/E is unavailable?
What are the company's customers, service mix, and revenue drivers within Medical/Nursing Services?
What is the cash flow trajectory behind the FY 2025 FCF of $26.6M after the FY 2024 FCF of $-44.8M?
What do the FY 2023 cash and debt figures show, since both are N/A in the source data?
What is the basis for the GuruFocus and Yahoo Finance valuation-downside commentary, and what assumptions sit behind it?

INNV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for InnovAge Holding Corp. (INNV) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INNV Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 17h ago

Earnings To Watch: InnovAge Holding Corp (INNV) Q1 2027 -- GF Value Sees 20% Downside

Yahoo Finance report covering InnovAge Holding Corp. (INNV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 20h ago

InnovAge (INNV) Chief Legal Officer Nicole Damato Sells 3,402 Sh

GuruFocus report covering InnovAge Holding Corp. (INNV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 23h ago

InnovAge Holding Corp. (NASDAQ:INNV) Stock Short Interest Declines 57.0%

MarketBeat report covering InnovAge Holding Corp. (INNV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Quiver Quantitative • 1d ago

InnovAge Holding Corp. ($INNV) CEO 2026 Pay Revealed

Quiver Quantitative report covering InnovAge Holding Corp. (INNV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Insider Selling: InnovAge (NASDAQ:INNV) Insider Sells 3,402 Shares of Stock

MarketBeat report covering InnovAge Holding Corp. (INNV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

InnovAge (NASDAQ:INNV) Stock: Insider Carson Anderson & Stow Welsh Sells 1,500,000 Shares

MarketBeat report covering InnovAge Holding Corp. (INNV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

InnovAge (NASDAQ:INNV) Major Shareholder Sells 1,500,000 Shares of Company Stock

MarketBeat report covering InnovAge Holding Corp. (INNV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

InnovAge (NASDAQ:INNV) Sees Strong Trading Volume - What's Next?

MarketBeat report covering InnovAge Holding Corp. (INNV) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INNV Bull vs. Bear Conversation Board — What's Your Call at $9.19?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INNV 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $9.98 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is INNV (D+ • RQD 52/100) a Buy at $9.24?

Welcome to the INNV (InnovAge Holding Corp.) Roar Pit. Current RQD Composite is 52/100 (Roarable Sell — Weak Fundamentals / Trim) in Medical/Nursing Services. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $7.58 (-18.0%)

Spot @ $9.24

Pump the brakes on INNV — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on INNV, but look at what you are paying: current EV/EBITDA multiples with 18.0% gross margins. Unless InnovAge Holding Corp. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $10.72 (+16.0%)

Spot @ $9.24

INNV cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on INNV, the market is fixating on short-term headline noise in Medical/Nursing Services and ignoring the balance sheet and cash flow trajectory. At $9.24 (52-wk range $3.93 - $12.64), any beat on forward guidance forces shorts and underweight funds to chase.